VOLL MARK 4

What Happened Mark Voll, Chief Financial Officer of RenovoRx, participated in a private placement on March 20, 2026, acquiring 97,200 common shares and 48,600 derivative securities (warrants). The filing (reported March 24, 2026) shows the aggregate purchase price for the securities was $100,000. This was a purchase (private placement), which insiders buying stock or related securities is generally viewed as a more informative/bullish action than routine sales.

Key Details

• Transaction date: March 20, 2026; Form 4 filed March 24, 2026 (filed timely within SEC reporting window).
• Securities acquired: 97,200 common shares (purchase) and 48,600 warrants (derivative purchase).
• Aggregate consideration: $100,000 (per footnote); per‑share or per‑warrant price not disclosed on the form.
• Warrants: exercisable immediately; expire on the earlier of March 30, 2029 or 30 days after the issuer reports at least $1.5M in product sales revenue for any calendar quarter (see footnote).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction code: P = Purchase. No tax withholding, 10b5-1 plan, or late-file indication noted.

Context The derivative portion are warrants (rights to buy shares) that can be exercised immediately under the terms disclosed, with an unusual expiration tied to a product-sales milestone. Because this was a private placement rather than an open-market buy, the exact per-security price wasn’t shown on the form (only the aggregate $100,000). Purchases by a company officer like the CFO can be of interest to retail investors, but they do not guarantee future company performance.